Physician profile

Sonya R Mcwilliams

Nurse Practitioner · Knoxville, TN

NPI 1073558334

$2,855.58

in general payments reported to CMS, 2019-2025

42 companies · $616 in 2025

The $616 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

See the full distribution for Nurse Practitioner

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,452.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $615.14 2021-2025 Wegovy
Lilly USA, LLC $361.22 2021-2025 Mounjaro, Zepbound
Daiichi Sankyo INC. $183.74 2021-2023 Injectafer
Phathom Pharmaceuticals, INC. $132.92 2024-2025 Voquezna
Teleflex LLC $109.24 2023-2025 Quikclot, Quikclot, Titan Sgs Bailout Chuck
Medtronic, INC. $98.72 2022-2025 Progrip, Maxtack
Baxter Healthcare $97.12 2022-2025 Perclot, Tisseel
Takeda Pharmaceuticals U.S.A., INC. $96.08 2021-2023 Gattex
Ethicon US, LLC $85.38 2021-2023 Echelon; Endopath, Ethicon, Vistaseal
Abbvie INC. $79.44 2021-2024
Acera Surgical, INC. $78.79 2024-2025 Restrata Wound Matrix
Olympus America INC. $67.17 2021-2023 Olympus
Shield Therapeutics INC $60.33 2024-2025
Vertex Pharmaceuticals Incorporated $55.80 2024-2025
Rhythm Pharmaceuticals, INC. $52.75 2024-2025 Imcivree
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $52.41 2022-2023 Seglentis
Davol INC. $47.30 2024
Inspire Medical Systems, INC. $46.70 2024 Inspire
Xeris Pharmaceuticals, INC. $45.94 2021
Currax Pharmaceuticals LLC $37.42 2022-2023 Contrave
Boston Scientific Corporation $35.70 2021
Heron Therapeutics, INC. $34.08 2021-2022
Merck Sharp & Dohme LLC $33.84 2024-2025 Lynparza, Keytruda
W. L. Gore & Associates, INC. $26.58 2025 Gore Enform Preperitoneal Biomaterial
Conmed Corporation $24.92 2024
Ambu INC. $23.86 2022
Hologic Sales and Service, LLC $22.47 2023 Coolseal Generator
Intuitive Surgical, INC. $21.28 2024
Astrazeneca Pharmaceuticals LP $21.23 2024
Innocoll Pharmaceuticals Limited $19.92 2021
Mallinckrodt Hospital Products INC. $19.56 2021
Endo Pharmaceuticals INC. $18.29 2023 Nascobal
Solventum Corporation $18.24 2025 V.A.C.Ulta, Prevena
Pacira Pharmaceuticals Incorporated $17.87 2021
Ipsen Biopharmaceuticals, INC $15.83 2022
Puma Biotechnology, INC. $15.62 2024
E.R. Squibb & Sons, L.L.C. $14.50 2022
Eagle Pharmaceuticals, INC. $14.32 2023
Integra Lifesciences Corporation $13.89 2023 Integra, Omnigraft, Integra Dermal Regeneration Template
Smith+Nephew, INC. $13.56 2021
Intra-Sana Laboratories $13.53 2023 Reltone 200 Mg, Reltone 400 Mg, Glycate
Sanara Medtech INC. $12.88 2023 Celleraterx

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sonya R Mcwilliams

$2,855.58

in general payments reported 2019-2025

Years
2021-2025
Top company
Novo Nordisk INC
Context
The $616 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

https://glasscript.com/doctor/10716085/sonya-r-mcwilliams

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.